Fixed dose-rate gemcitabine with cisplatin patients with pancreatic adenocarcinoma - single institution experience

被引：0
|
作者：
Mihaylova, Z. [1 ]
Raynov, J. [1 ]
Vladov, N. [2 ]
Mihaylov, V [2 ]
Kazarov, K. [3 ]
Dunkov, Z. [3 ]
机构：
[1] Mil Med Acad, Dept Hematol & Oncol, Sofia, Bulgaria
[2] Mil Med Acad, Dept Liver Surg, Sofia, Bulgaria
[3] Mil Med Acad, Dept Gastroenterol, Sofia, Bulgaria
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas
    Feliu, J.
    Saenz, J. Garcia
    Jaraiz, A. Rodriguez
    Castanon, C.
    Cruz, M.
    Fonseca, E.
    Lomas, M.
    Castro, J.
    Jara, C.
    Casado, E.
    Leon, A.
    Baron, M. Gonzalez
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 419 - 426
  • [2] Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas
    J. Feliu
    J. García Sáenz
    A. Rodríguez Jaráiz
    C. Castañón
    M. Cruz
    E. Fonseca
    M. Lomas
    J. Castro
    C. Jara
    E. Casado
    A. León
    M. González Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 419 - 426
  • [3] Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma
    Mane, Joan M.
    Sancho, Aintzane
    Munoz, Alberto
    Rubio, Itziar
    Fernandez, Ricardo
    Carrera, Sergio
    Fuente, Natalia
    Ballesteros, David
    Casas, Raquel
    Marrodan, Ines
    Mielgo, Xabier
    Lopez-Vivanco, Guillermo
    [J]. TUMORI, 2010, 96 (03) : 405 - 410
  • [4] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vaccaro, Vanja
    Bria, Emilio
    Sperduti, Isabella
    Gelibter, Alain
    Moscetti, Luca
    Mansueto, Giovanni
    Ruggeri, Enzo Maria
    Gamucci, Teresa
    Cognetti, Francesco
    Milella, Michele
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (28) : 4511 - 4519
  • [5] First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
    Vanja Vaccaro
    Emilio Bria
    Isabella Sperduti
    Alain Gelibter
    Luca Moscetti
    Giovanni Mansueto
    Enzo Maria Ruggeri
    Teresa Gamucci
    Francesco Cognetti
    Michele Milella
    [J]. World Journal of Gastroenterology, 2013, (28) : 4511 - 4519
  • [6] Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Ko, AH
    Dito, E
    Schillinger, B
    Venook, AP
    Bergsland, EK
    Tempero, MA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 379 - 385
  • [7] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    Feliu, J.
    Borrega, P.
    Leon, A.
    Lopez-Gomez, L.
    Lopez, M.
    Castro, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Martinez, V.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 215 - 221
  • [8] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    J. Feliu
    P. Borrega
    A. León
    L. López-Gómez
    M. López
    J. Castro
    C. Belda-Iniesta
    J. Barriuso
    V. Martínez
    M. González-Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 215 - 221
  • [9] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic carcinoma
    Espinosa, E.
    Feliu, J.
    de Castro, J.
    Belda, C.
    Casado, E.
    Herrero, A.
    Sereno, M.
    Pinto, A.
    Gomez, C.
    Baron, M. Gonzalez
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
    C Bengala
    V Guarneri
    E Giovannetti
    M Lencioni
    E Fontana
    V Mey
    A Fontana
    U Boggi
    M Del Chiaro
    R Danesi
    S Ricci
    F Mosca
    M Del Tacca
    P F Conte
    [J]. British Journal of Cancer, 2005, 93 : 35 - 40
12345